The Texas Spine and Neurosurgery Journal

The goal of this academic publication is to inform and educate physicians and their staff about spine care and neurosurgery. 

A Word From The Editor

Steven C. Zielinski, MD, CM, FRCSC

Diplomate of the American Board of Neurological Surgery

And So It Begins….
Welcome. This is the first issue of the Texas Spine and Neurosurgery Journal. Our goal is to aid and inform family doctors and community providers as well as their staff. We want to help practitioners treat their patients with spine and neurosurgery issues.  If you know of someone who might benefit from a subscription, or if you have a question or topic for review, please contact us at [email protected].  The territory for the Journal continues to grow, but presently extends from Dallas to the Gulf coast and from Gatesville to Palestine. 

Expert Opinion:  Trigeminal Neuralgia

Jonathan White, MD, FAANS, FACS
Professor, Neurological Surgery
UT Southwestern Medical Center
Residency Program Director
Birsner Family Professorship in Neurological Surgery

For brevity, this review will focus on bridging warfarin anticoagulation with enoxaparin therapy.  With the push toward the new oral anticoagulants (NOACs), warfarin gets a bad rep, but reality is that the cost of NOACs and the mountains of data from years of warfarin use still keep its therapeutic value alive.

An obvious question: why not bridge with a NOAC?  Fast-onset, fast washout, little monitoring needed…but still considered too risky.  For now, NOACs are not recommended in CHEST 2012 for bridging therapy.    Post-marketing data on the single approved NOAC reversal agent idalucizumab for dabigatran and trial data for andexanet alfa may change this scenario soon, but at this time only injectable agents are recommended, with enoxaparin (and dalteparin) most commonly used in clinical practice.

So, how to bridge, if you must?  A successful plan addresses the following:

• The patient’s thromboembolic risk: High, Medium, or Low.
• The procedure’s bleeding risk: High, Medium, or Low.
• The who and how of the regimen.

Thromboembolic risk classification is based on patient’s PMH:

• if Atrial Fibrillation:  the patient’s CHADS2 Score
• if Mechanical Valve: Which Type? Any Problems? Is it an old-style aortic valve prosthesis, or a mitral valve prosthesis?
• if VTE/PE:  When? Any Problems?

High Risk: warfarin held 5 days pre-procedure, enoxaparin 1.5 mg/kg/day once INR<2.0 or 2.5 (depending on indication) with 0.75 mg/kg x1given 24 hours prior to surgery, for patients with—

• An AFib CHADS2 Score of 5-6
• A mitral valve prosthesis, or old-style caged ball or tilting disk aortic valve prosthesis; also a  stroke/TIA within previous 6 months
• A VTE within 3 months, an extreme thrombophilic risk from Protein C, S, or Antithrombin III deficiency, or documented Antiphospholipid Antibody Syndrome

Moderate Risk: the same pre-procedure regimen as above.  These individuals have—

• a CHADS2 Score of 3-4
• a bileaflet aortic valve prosthesis with any additional comorbidities:  AFib, prior stroke/TIA, hypertension, diabetes, CHF, or age >75
• Single VTE within the past 3-12 months, recurrent VTE, active cancer treated within 6 months, or non-severe thrombophilia such as heterozygous Factor V Leiden.

Low Risk:   warfarin stopped 5 days prior to, and restarted the first night post-procedure, if hemostasis is assured.  These are patients with—

• a CHADS2 score of 0-2
• a bileaflet aortic valve prosthesis without AFib or other risk factors for stroke.
• A single VTE > 12 months ago, and no other risk factors.

The bleeding risk depends upon the type of surgery:

• High risk: Surgeries with duration > 1 hr, major abdominal procedures, kidney/breast/lung biopsy, total joint replacement, radical prostatectomy, heart valve replacement, and neurosurgery.  These will be dosed with enoxaparin 40 mg/day post-procedure, starting after hemostasis, usually within 24-48 hours.
• Medium risk: Procedures not included in high or low risk categories.  Post-procedural enoxaparin is often ordered for 1.5 mg/kg/day beginning 48 hours post-op.  These surgeries can be elevated to high risk, and/or post-procedure enoxaparin regimen adjusted in between low or high risk levels, at professional discretion.
• Low risk procedures can often allow continuous anticoagulation.  These include dental, cataract, endoscopy without polypectomy, joint injections, or minor dermatological work. If anticoagulation interruption is deemed necessary, enoxaparin may be begun at 1.5 mg/kg/day, beginning 24 hours post-procedure.

Medium and High-risk are often combined in hospital surgical protocols, since there are no clear-cut CHEST 2012 guidelines for moderate risk procedures.

Combining these pre-op and post-procedure thrombotic and bleeding risks together for, example, a warfarin patient with PMH of recurrent VTE undergoing spinal surgery might offer the following bridging plan:

• Hold warfarin five days prior to planned procedure
• Begin enoxaparin therapy at 1.5 mg/kg/day once the INR has dipped below threshold of 2.5 or 2.0, depending on the indication.
• 24 hr pre-procedure, dose enoxaparin 0.75 mg/kg x 1.
• Order an INR or other factor-specific test just prior to surgery to confirm subtherapeutic range.  (INRs still too high can be dosed with Vitamin K or other agent per specialist consult.)
• Post-procedure, resume warfarin that evening at patient’s usual dose, and enoxaparin 40 mg/day once hemostasis has occurred.
• Order INR for post-op days 3 and 5, and Platelet Counts for days 5 and14 (monitoring enoxaparin)
• Continue enoxaparin 40 mg/day with warfarin until the INR is within therapeutic range for 2 consecutive days.

The who and how of the regimen is the last but most important of the entire assessment.  Patients may not ask enough questions about instructions, so it falls to the provider to ensure that the bridging regimen can be followed.  Who is capable of and therefore will be administering the injections, if not the patient themselves? How will the patient will be able to pay for the enoxaparin itself? A price check at one Texas Walmart showed the cost of a 40mg syringe at $11, a 60mg syringe about $30, and other strengths priced even higher.  A Medicare patient in the doughnut hole may not be able to afford that, and might not say so, with possible disastrous results.  The physician should therefore ask pointed questions beforehand about the patient’s insurance coverage and caregiver support.  It would be good practice to also have office staff follow up with the patient’s pharmacy to ensure that the enoxaparin has been picked up, and with the patient/caregiver at home to make sure they have begun administration by the third day pre-procedure.

Perioperative warfarin management is fraught with risk.  Current guidelines, while just that—guidelines, can be used to assist in pre-and post-procedure orders and decrease the liability of the individual practitioner.  They are, however, no substitute for careful clinical consideration of patient’s PMH and comorbidities. Professional judgment can and should factor in all preparation surrounding an upcoming procedure to yield the best outcome for the patient.

Jenessa Burney gratefully acknowledges the lecture notes of “Perioperative Management of Warfarin Interruption”, prepared by Victoria Lambert, PharmD, CACP,  William Backus Hospital, University of Connecticut, 2015.

References

Brianna Crenwelge, B.S.
Texas A&M Nutritional Sciences 

Diet is responsible for forming cells in the body that have a direct correlation with progress after surgical intervention. Adequate nutrition is important to promote healing, particularly for spinal surgery where bony fusion is desired. A proper diet including particular vitamins and minerals can help promote the body’s natural ability to create bony fusion around instrumentation to stabilize the spine in addition to increase current bony mass. Vitamin D and Calcium Carbonate combined are shown to slow down and in certain cases reverse osteoporosis which indicates stimulation of proper bone growth. Calcium is required to stimulate bone growth which requires Vitamin D for Calcium absorption and use. Vitamin D can be absorbed by the body two ways, one through direct sunlight and the other through diet. With increased age and higher melatonin count in the skin, the human body’s ability to absorb Vitamin D from direct sunlight decreases where diet becomes more prevalent.  A high Vitamin D diet includes foods similar to eggs, butter, fatty fish, orange juice, and fortified foods as well as supplementation. For supplementation, a recommendation could be 1,000 mg Calcium Carbonate combined with 5,000 IU Vitamin D taken daily.

Adequate nutrition is likewise vital for efficient wound healing. Protein, Vitamin C, Vitamin A, Zinc, and appropriate blood sugar levels are most effective to provide the body with the necessary requirements to heal. Proper protein sources include meats, eggs, milk, beans, tofu, and soy products. Vitamin C is found in citrus fruits, tomatoes, peppers, and greens including but not limited to spinach, broccoli, brussel sprouts, and cabbage. Vitamin A is found in dark green leafy vegetables, liver, fortified dairy and cereal products, and orange and yellow vegetables. Zinc is found in red meats, seafood, and fortified cereals. If your patient has diabetes, it is important to closely monitor their blood sugar levels to decrease infection rates, longer hospital stays, and additional admits to the hospital.  Specifically a high protein diet has been shown to decrease wounds and bed sores, and promote correct wound healing. Recommendations indicate to eat at minimum of 2-3 servings of protein a day or supplement with protein shakes if the patient has a low appetite or cannot chew. Adequate nutrition provides the human body with the necessary building blocks to form the crucial cells for bone growth and promote healing for a faster and more effective recovery. 

Texas Spine and Neurosurgery and Texas Spine and Neurosurgery Journal
are the property of Steven Zielinski MD PA, DBA Texas Spine and Neurosurgery.
All articles reflect the opinions of the individual authors and are not independently verified for accuracy. The Journal provides no recommendation for therapy of any individual patient but tries to promote the academic discussion of the topics covered.

Our mailing address is:

1000 West Hwy 6 Suite 430
Waco, Texas
76712

Phone Numbers:
(844) Meet Dr Z
(844) 633-8379